文献速递神经肌肉病

MPZ突变相关腓骨肌萎缩症疾病进展的纵向研究

Disease Progression in Charcot-Marie-Tooth Disease Related to MPZ Mutations: A Longitudinal Study.
PubMed 文献 · Ann Neurol · 2022-10-28

该纵向自然史研究纳入遗传性神经病联盟13个中心的139例MPZ神经病患者,用CMTES和CMTES-R评估5年内变化;混合回归模型显示CMTES在第2-5年较基线显著变化,轴索型2年变化较脱髓鞘型更大,中度基线严重度者变化更明显。

要点

  • CMTES对成人轴索型MPZ神经病随时间变化敏感,对脱髓鞘型不敏感。
  • 轴索型2年CMTES平均变化1.30分(p=0.016),脱髓鞘型0.06分(p=0.889)。
  • 基线CMTES 8-14分者2年平均变化1.14分(p=0.025),变化大于轻度或重度者。

核心结论

  • CMTES对成人轴索型MPZ神经病随时间变化敏感,但对脱髓鞘型不敏感。
  • 基线疾病严重度为中度者CMTES变化最大,特定MPZ突变患者进展高度可变。

研究设计与样本

  • 遗传性神经病联盟13个中心的纵向自然史研究,纳入139例MPZ神经病患者,评估5年内CMTES和CMTES-R变化。

主要发现

  • 基线平均CMTES为10.84(标准差6.0,范围0-28),平均CMTES-R为14.60(标准差7.56,范围0-32)。
  • 混合回归模型显示CMTES在第2-5年较基线显著变化,2年时较基线平均变化0.87分(p=0.008)。
  • 轴索型2年CMTES平均变化1.30分(p=0.016),脱髓鞘型0.06分(p=0.889)。
  • 基线CMTES 8-14分者2年平均变化1.14分(p=0.025),基线CMTES 0-7分者-0.03分(p=0.958),基线CMTES≥15分者0.25分(p=0.6897)。
  • 携带特定MPZ突变患者的进展高度可变。

临床怎么用

  • 作者认为这些发现将为未来MPZ神经病的临床试验提供信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The paucity of longitudinal natural history studies in MPZ neuropathy remains a barrier to clinical trials. We have completed a longitudinal natural history study in patients with MPZ neuropathies across 13 sites of the Inherited Neuropathies Consortium. METHODS: Change in Charcot-Marie-Tooth Examination Score (CMTES) and Rasch modified CMTES (CMTES-R) were evaluated using longitudinal regression over a 5-year period in subjects with MPZ neuropathy. Data from 139 patients with MPZ neuropathy were examined. RESULTS: The average baseline CMTES and CMTES-R were 10.84 (standard deviation [SD] = 6.0, range = 0-28) and 14.60 (SD = 7.56, range = 0-32), respectively. A mixed regression model showed significant change in CMTES at years 2-5 (mean change from baseline of 0.87 points at 2 years, p = 0.008). Subgroup analysis revealed greater change in CMTES at 2 years in subjects with axonal as compared to demyelinating neuropathy (mean change of 1.30 points [p = 0.016] vs 0.06 points [p = 0.889]). Patients with a moderate baseline neuropathy severity also showed more notable change, by estimate, than those with mild or severe neuropathy (mean 2-year change of 1.14 for baseline CMTES 8-14 [p = 0.025] vs -0.03 for baseline CMTES 0-7 [p = 0.958] and 0.25 for baseline CMTES ≥ 15 [p = 0.6897]). The progression in patients harboring specific MPZ mutations was highly variable. INTERPRETATION: CMTES is sensitive to change over time in adult patients with axonal but not demyelinating forms of MPZ neuropathy. Change in CMTES was greatest in patients with moderate baseline disease severity. These findings will inform future clinical trials of MPZ neuropathies. ANN NEUROL 2023;93:563-576.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Fridman V, Sillau S, Bockhorst J, et al. Disease Progression in Charcot-Marie-Tooth Disease Related to MPZ Mutations: A Longitudinal Study. Ann Neurol. 2022. PMID: 36203352. doi:10.1002/ana.26518

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。